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 Abstract 22 
New chemotherapeutic agents with novel mechanisms of action are in urgent need to combat the 23 
tuberculosis pandemic.  A library of twelve C8-linked pyrrolo[2,1-c][1,4]benzodiazepine(PBD)-24 
heterocyclic polyamide conjugates (1-12) was evaluated for anti-tubercular activity and DNA 25 
sequence selectivity.  The PBD-conjugates were screened against slow-growing Mycobacterium bovis 26 
BCG and M. tuberculosis H37Rv and fast-growing Escherichia coli, Pseudomonas putida and 27 
Rhodococcus sp. RHA1 bacteria.  DNase I footprinting and DNA thermal denaturation experiments 28 
were used to determine the molecules’ DNA recognition properties.  The PBD-conjugates were highly 29 
selective for the mycobacterial strains and exhibited significant growth inhibitory activity against the 30 
pathogenic M. tuberculosis H37Rv, with compound 4 showing MIC values (MIC = 0.08 mg/L) similar 31 
to those of rifampin and isoniazid.  DNase I footprinting results showed that the PBD-conjugates with 32 
three heterocyclic moieties had enhanced sequence selectivity and produced larger footprints with 33 
distinct cleavage patterns compared to the two-heterocyclic chain PBD-conjugates.  DNA melting 34 
experiments indicated a covalent binding of the PBD-conjugates to two AT-rich DNA-duplexes 35 
containing either a central GGATCC or GTATAC sequence and showed that the polyamide chains 36 
affect the interactions of the molecules with DNA.  The PBD-C8-conjugates tested in this study have 37 
a remarkable anti-mycobacterial activity and can be further developed as DNA-targeted anti-38 
tubercular drugs. 39 
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1. Introduction 43 
Tuberculosis (TB) is a global health challenge, with 9 million new cases and 1.5 million deaths 44 
reported in 2013.1  Furthermore, it is estimated that one third of the world’s population is infected 45 
with Mycobacterium tuberculosis, accounting for a large reservoir of the bacilli.1  The increasing 46 
incidence of TB is also linked to the steady increase in multi-drug and extensively-drug resistant 47 
 tuberculosis (MDR/XDR-TB) strains, which renders TB difficult to treat.1,2  Therefore, new 48 
antibiotics with novel and pleiotropic modes of action are urgently needed to combat the TB 49 
pandemic, the rise of resistant bacilli and also provide new, safer and shorter drugs regimens.  To this 50 
end, the complete reconstruction of the M. tuberculosis regulatory network 3 has laid the foundation 51 
for the development of DNA-targeted anti-mycobacterial agents.  The ability of DNA sequence-52 
selective agents to target specific promoter regions of the M. tuberculosis DNA can be exploited to 53 
disrupt the binding of mycobacterial transcription factors, induce bacterial cell death, overcome 54 
antimicrobial resistance and maximize therapeutic efficacy. 55 
DNA-targeted chemotherapeutic agents are an important class of compounds, which have long 56 
attracted interest due to their distinctive mode of action involving specific interactions with 57 
predetermined DNA sequences.4-7  Among these agents, pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) 58 
have played a major role in cancer and antibacterial chemotherapy.8, 9  PBDs are a family of 59 
antitumour-antibiotics first isolated from cultures of Streptomyces species.10  These molecules are 60 
DNA sequence-selective agents that covalently bind, via their N10-C11 imine functionality, to the 61 
C2-amino groups of guanine residues within the minor groove of DNA, spanning three DNA base 62 
pairs with a preference for Pu–G–Pu (where Pu = purine; G = guanine) sequences (Figure 1).9, 11  63 
PBD monomers block transcription by inhibiting RNA polymerase activity in a sequence-specific 64 
manner.12 65 
Since their discovery, several PBD analogues have been synthesised and extensively evaluated for 66 
their anticancer and antibacterial activities.8, 13-17  However, to our knowledge, there are only few 67 
studies focusing on the anti-mycobacterial activity of the PBDs.  Taylor and Thurston reported that 68 
PBD dimers, in which two PBD units are tethered through a C8/C8′′ diether linker to improve DNA-69 
binding affinity and sequence specificity, exhibited notable activity against a panel of rapid and 70 
relatively rapid-growing mycobacteria, Mycobacterium smegmatis, M. fortuitum, M. abscessus, M. 71 
phlei and M. aurum.18  Although showing anti-mycobacterial activity, the PBD dimers displayed 72 
significant cytotoxicity against human cell lines, especially compared to PBD monomers, and may be 73 
 only used as “drug of last resort” to treat intractable infections caused by multi-drug resistant 74 
pathogens.19  In another study, Kamal et al. showed that PBD-5,11-diones (PBD dilactams) inhibited 75 
the growth of Mycobacterium avium, M. intracellulare and M. tuberculosis.  PBD-dilactams stabilise 76 
duplex-DNA to a lesser extent than PBDs, as they lack the N10-C11 imine moiety responsible for the 77 
electrophilic alkylation of the C2-NH2 of guanine bases, thus resulting in a non-covalent DNA 78 
interaction and reduced antibacterial and anticancer potency.9, 20 79 
In the present study, we investigated the anti-mycobacterial activity and DNA binding properties of a 80 
library of twelve C8-linked PBD-heterocyclic polyamide conjugates (1-12) (Figure 2), which were 81 
previously shown to have strong in vitro anticancer activities. 21-23  The di- or tri-heterocyclic 82 
polyamide chains of 1-12 are comprised of combinations of pyrrole (Py), imidazole (Im) and thiazole 83 
(Th) rings known for their ability to modulate the ligands’ DNA-binding affinity.24  C8-linked PBD-84 
polyamide conjugates, unlike PBD dilactams, retain the ability to form covalent DNA-adducts, 85 
characteristic responsible for their improved cancer cell cytotoxicity and antibacterial activities,15 and 86 
have a more favourable cytotoxicity profile compared to the PBD dimers. 15,17   87 
PBD-conjugates 1-12 were screened against slow-growing Mycobacterium bovis BCG and M. 88 
tuberculosis H37Rv and fast-growing Escherichia coli, Pseudomonas putida and Rhodococcus sp. and 89 
minimum inhibitory concentration values (MIC) were determined.  Cytotoxicity against mouse 90 
macrophages RAW264.7 was also evaluated.  The DNaseI footprinting experiments and thermal 91 
denaturation assays were used to evaluate the DNA recognition properties of 1-12. 92 
2. Materials and methods 93 
C8-linked PBD-heterocyclic polyamide conjugates 94 
The twelve PBD-conjugates 1-12 were synthesised and purified using published synthetic routes21, 22 95 
and dissolved in DMSO prior to use.  96 
Microorganisms and mammalian cells 97 
 Mycobacterium bovis BCG Pasteur (ATCC 35734) and M. tuberculosis H37Rv (ATCC 27294), and 98 
Escherichia coli K12 (ATCC 53323), Pseudomonas putida KT2442 (ATCC 47054) and Rhodococcus 99 
sp. RHA1 were used to screen the antibacterial activity of the PBD conjugates.  Murine macrophages 100 
RAW264.7 (ATCC TIB71) were used in this study to evaluate the cytotoxicity of the PBD-101 
conjugates. 102 
Mammalian macrophage cytotoxicity assay using resazurin assay 103 
The quantitation of eukaryotic cell toxicity was carried out as previously described.25  104 
Antibacterial assay against E. coli, P. putida and Rhodococcus sp.  105 
The evaluation of growth inhibition of the PDB-conjugates against E. coli, P. putida and Rhodococcus 106 
sp. was performed using the spot culture growth inhibition assay (SPOTi) in 24 well plates.26  A seed 107 
culture of each bacteria was prepared in Luria Bertani (LB) broth and grown overnight at 37 ºC with 108 
shaking at 200 rpm.  Rhodococcus sp. was grown in LB broth at 30 ºC with shaking at 200 rpm.  109 
Dilutions of the PBD-conjugates were performed in sterile DMSO at concentrations one thousand-110 
fold more concentrated than the concentrations to be tested.  2 µL of each dilution were dispensed in 111 
each well of the 24 well plates, and 2 mL of LB agar were added to each well, and mixed.  2 µL of 112 
each inoculum containing approximately 105 colony-forming units (CFUs)/mL were carefully 113 
dispensed into the middle of the well on the surface of the solidified agar.  The plate was incubated 114 
overnight at 37 ºC for E. coli and P. putida, and at 30 ºC for Rhodococcus sp.  The plates were 115 
visually inspected and minimum inhibitory concentrations (MIC) values were recorded as the lowest 116 
concentration of PBD-conjugates where no growth was observed.  Kanamycin was included as 117 
positive control. 118 
Anti-mycobacterial screening using HT-SPOTi 119 
M. bovis BCG and M. tuberculosis H37Rv were grown in Middlebrook 7H9 broth supplemented with 120 
0.02% (v/v) glycerol, 0.05% (v/v) tween-80 and 10% (v/v) albumin, dextrose and catalase (ADC; BD 121 
 Biosciences) as a rolling culture at 2 rpm and 37 C, and as a stand culture at 37 C.  The 122 
antimycobacterial activities of the compounds were tested following the HT-SPOTi guidelines.26,27  123 
HT-SPOTi is a high-throughput growth inhibition assay conducted in a semi-automated 96 well plate 124 
format.  Compounds dissolved in DMSO at a final concentration of 50 mg/mL were serially diluted 125 
and dispensed in a volume of 2 µL into each well of a 96 well plate to which 200 µL of Middlebrook 126 
7H10 agar medium kept at 55 C supplemented with 0.05% (v/v) glycerol and 10% (v/v) OADC was 127 
added.  Wells with no compounds (DMSO only) and isoniazid (positive control) were used as 128 
experimental controls.  To all the plates, a drop (2 µL) of mycobacterial culture containing 2 × 103 129 
CFUs was spotted in the middle of each well and the plates were incubated at 37 C for 7 days.  The 130 
MICs were determined as the lowest concentration of each compound where no mycobacterial growth 131 
was observed. 132 
DNase I footprinting assay 133 
Footprinting reactions were performed as previously described28 using the DNA fragments HexAfor 134 
and HexBRev, which together contain all 64 symmetrical hexanucleotide sequences.   The DNA 135 
fragments were obtained by cutting the parent plasmids with HindIII and SacI (HexA) or EcoRI and 136 
PstI (HexBRev) and were labelled at the 3’-end with [α-32P]dATP using reverse transcriptase.  After 137 
gel purification the radiolabelled DNA was dissolved in 10 mM Tris-HCl pH 7.5 containing 0.1 mM 138 
EDTA, at a concentration of about 10 c.p.s per µL as determined on a hand held Geiger counter.  1.5 139 
µL of radiolabelled DNA was mixed with 1.5 µL ligand that had been freshly diluted in 10 mM Tris -140 
HCl pH 7.5, containing 10 mM NaCl.  The complexes were left to equilibrate for at least 12 hours 141 
before digesting with 2 µL DNase I (final concentration about 0.01 units/ml).  The reactions were 142 
stopped after 1 minute by adding 4 µL of formamide containing 10 mM EDTA and bromophenol blue 143 
(0.1% w/v).  The samples were then heated at 100 °C for 3 minutes before loading onto 8% denaturing 144 
polyacrylamide gels containing 8 M urea.  Gels were fixed in 10% acetic acid, transferred to 3MM 145 
paper, dried and exposed to a phosphor screen overnight, before analysing with a typhoon 146 
phosporimager. 147 
 DNA thermal denaturation studies 148 
Fluorescence melting curves were determined in a Roche LightCycler, using a total reaction volume 149 
of 20 µL.  For each reaction the final oligonucleotide concentration was 0.25 µM, diluted in 10 mM 150 
sodium phosphate pH 7.4 containing 100 mM NaCl.  The experiments used the duplexes 5’-F-151 
AAAAGGATCCAAAA/5’-TTTTGGATCCTTTT-Q and 5’-F-AAAAGTATACAAAA/5’-152 
TTTTGTATACTTTT-Q (F = fluorescein and Q = dabcyl).  In a typical experiment the samples were 153 
first denatured by heating to 95 °C at a rate of 0.1 °C s–1.  The samples were then maintained at 95 °C 154 
for 5 min before annealing by cooling to 25 °C at 0.1 °C s–1 (this is the slowest heating and cooling 155 
rate for the LightCycler).  They were held at 25 °C for a further 5 min and then melted by heating to 156 
95 °C at 0.1 °C s–1.  Recordings of the fluorescence emission at 520 nm were taken during both the 157 
melting steps as well as during annealing.  The data were normalized to show the fractional change in 158 
fluorescence for each sample between the starting and final values.  Tm values were determined from 159 
the first derivatives of the melting profiles using the Roche LightCycler software.  160 
3. Results 161 
Growth inhibition of Mycobacterium spp.  162 
In Table 1 are illustrated the results of the anti-tubercular and anti-bacterial screening, the 163 
cytotoxicity evaluation and the selectivity index (SI) of 1-12.  Compounds 1-12 were tested for 164 
growth inhibition against two slow-growing mycobacteria, Mycobacterium bovis BCG and M. 165 
tuberculosis H37Rv.  The PBD-conjugates’ MIC values against M. tuberculosis ranged from 0.08 to 166 
5.19 mg/L, whereas the MIC values against M. bovis ranged from 0.04 to 20 mg/L.  Dipyrrole-167 
including PBD-conjugate 4 (Py-Py-PBD) exhibited the highest growth inhibitory activity against M. 168 
tuberculosis with a MIC value of 0.08 mg/L.  Compounds 5 (Py-Py-Im-PBD), 7 (Im-Im-Py-PBD), 9 169 
(Py-Py-Th-PBD), 10 (Py-Th-Py-PBD) and 12 (Py-Py-Py-PBD) inhibited the growth of M. 170 
tuberculosis at 0.16 mg/L concentration.  PBD-conjugate 1 (Py-Th-PBD) was active against M. 171 
tuberculosis and M. bovis at 0.31 and 0.16 mg/L, respectively, whereas compound 2 (Th-Py-PBD) 172 
 inhibited the growth of both mycobacteria at 0.63 mg/L.  Compounds 6 (Py-Im-Py-PBD) and 8 (Im-173 
Im-Im-PBD) were found to be 60-fold more active against M. tuberculosis (0.32 mg/L) than M. bovis 174 
BCG (20 mg/L), whereas PBD-conjugates 7, 9 and 10 were two-fold more active against M. bovis 175 
(0.08 mg/L) than M. tuberculosis (0.16 mg/L).  Pyrrole-including PBD-conjugates 4 and 12 showed 176 
the highest growth inhibitory activity against M. bovis with a MIC of 0.04 mg/L.  On the other hand, 177 
thiazole-including PBD-conjugates 3 (Th-Th-PBD) and 11 (Th-Th-Th-PBD) exhibited the lowest 178 
growth inhibitory activity against both M. tuberculosis and M. bovis BCG with values of 5.19 and 20 179 
mg/L, respectively.  First-line anti-tubercular drugs isoniazid and rifampin were used as positive 180 
controls and inhibited the growth of both mycobacterial strains at 0.05 mg/L. 181 
Antibacterial activity on E. coli K12, P. putida KT2442 and Rhodococcus sp. RHA1 182 
In order to evaluate the mycobacterial specificity of PBD-conjugates 1-12 in whole cell experiments 183 
and determine whether the compounds selectively affected slow-growing mycobacteria in comparison 184 
with fast-growing bacteria, we investigated the growth inhibitory activities of 1-12 against Gram-185 
positive Rhodococcus sp. RHA1 and Gram-negative Escherichia coli K12 and Pseudomonas putida 186 
KT2442 bacteria.  The results in Table 1 show that the majority of PBD-conjugates (1, 4-7, 9, 10 and 187 
12) had a significant growth inhibitory activity against E. coli and Rhodococcus sp. with a MIC value 188 
of 1.25 mg/L.  Interestingly, PBD-conjugate 8 was 150-fold more active against M. tuberculosis (0.32 189 
mg/L) than Gram-negative E. coli and P. putida (>50 mg/L), whereas thiazole-containing PBD-190 
conjugates 3 and 11 were 10-fold more active against M. tuberculosis (5.19 mg/L) than E. coli, P. 191 
putida and Rhodococcus sp (>50 mg/L) strains.  Tri-pyrrole-including PBD-conjugate 12 was active 192 
against P. putida at 5 mg/L, whereas compounds 4 and 5 inhibited the growth of this bacterium at 10 193 
mg/L.  Compounds 7, 9 and 10 were found to be approximately 300-fold more active against M. 194 
tuberculosis (0.16 mg/L) than P. putida (50 mg/L).  The aminoglycoside antibiotic kanamycin was 195 
used as a positive control and inhibited the growth of E. coli and P. putida at 1.0 mg/L and 196 
Rhodococcus sp. at 10 mg/L.   197 
 198 
 Macrophage RAW264.7 cytotoxicity 199 
The PBD-conjugates displayed various degrees of cytotoxicity against mammalian macrophages 200 
RAW264.7 with GIC50 values ranging from 1.66 to 4.45 mg/L.  The values of the Selectivity Index 201 
(SI), which is the ratio between macrophage half-growth inhibition concentration (GIC50) and MIC 202 
against the virulent H37Rv strain, ranged from 0.32 to 30.1, with PBD-conjugate 4 (Py-Py-PBD) 203 
exhibiting the highest specificity (SI = 30.1) amongst the library members.  PBD-conjugates 5, 7, 9, 204 
10 and 12 exhibited a SI of 10.4, whereas 1 had a SI of 14.4.  Thiazole-including PBD-conjugates 3 205 
and 11 showed the lowest specificity, with SI values of 0.46 and 0.32, respectively.  206 
DNase I footprinting 207 
DNase I footprinting was used to identify the binding sites of the PBD-conjugates, using the DNA 208 
fragments HexAfor and HexBrev,28 which together contain all 64 possible symmetrical 209 
hexanucleotide sequences.  The results are shown in Figure 3.  The left hand panels show the 210 
footprints with 10 µM of compounds 2, 3, 5, 7, 9 and 10 with HexAfor and HexBrev, while the two 211 
panels on the right show examples of the concentration dependence of the footprints with 5 and 9 on 212 
HexAfor.  It is evident that compounds 5, 9 and 10 produced large footprints in both HexAfor and 213 
HexBrev, while compound 7 produced fewer footprints including two shorter footprints (4a and b) 214 
within site 4.  Each of these ligands produced a distinct cleavage pattern and the location of the major 215 
footprints is indicated in Figure 4.  All these compounds contain three rings conjugated to the PBD.  216 
A few weaker footprints were seen with the compounds that only contain two conjugated rings.  217 
Compound 2, which contains thiazole and pyrrole rings, produced footprints at sites 2, 4 and 8, while 218 
no footprints were seen with 3, which contains two thiazole rings.  It is clear that addition of the 219 
heterocycles affects the interaction of PBD with DNA.  PBD-conjugates 5 (Py-Py-Im-PBD), 9 (Py-220 
Py-Th-PBD) and 10 (Py-Th-Py-PBD) bound to sites 1, 2, 3 and 4 within HexBrev, and to sites 6, 7, 8 221 
and 9 within HexAfor, while the footprint at site 5 in HexBrev is only evident with compounds 5 and 222 
9.  Compound 7 bound to fewer sites with clear footprints limited to sites 3, 4a and 4b on HexBrev 223 
and site 8 on HexAfor.  Although each ligand produced a characteristic cleavage pattern, it is 224 
 noticeable that many of the footprints contained a short A/T tract followed by a guanine.  The two 225 
right hand panels of Figure 3 show the concentration dependence of the footprints with 5 and 9 on the 226 
HexAfor fragment.  At 5 µM concentration 5 produced a single footprint located in the lower part of 227 
site 8 within the sequence 5’-GCGCTTAAGTACT.  Compound 9 produced footprints that persisted 228 
to lower concentrations, and the protections at the lower part of site 8 and in the centre of site 7 (5’-229 
TAAACGTT) were still evident with 0.5 µM ligand. 230 
DNA Melting Studies 231 
In order to further evaluate the contribution of the heterocyclic chains to the DNA recognition 232 
properties of the PBD-conjugates, the effects of the ligands on DNA-melting temperature were 233 
analysed using two fluorescently-labelled 14-mer DNA duplexes.  These AT-rich DNA duplexes 234 
contained either a central GGATCC or GTATAC and the results with 0.5 µM ligand are shown in 235 
Figure 5.  It can be seen that all four of these ligands stabilised the duplexes and produced transitions 236 
at elevated temperatures.  Since the ligands were covalently attached to the DNA, the Tm values of 237 
each transition did not change with the ligand concentration.  However, the relative proportions of the 238 
different components were altered, so that a greater fraction of the higher Tm was evident with higher 239 
ligand concentrations.  Each of these duplexes contains more than one guanine with which the 240 
conjugates could attach (two guanines for GTATAC and four for GGATCC) and further transitions 241 
were observed at higher ligand concentrations, as evident for 10 with both oligonucleotide duplexes.  242 
At a concentration of 0.5 µM the ligand was in excess of the target duplex (0.25 µM).  The fraction of 243 
the melting transition that has shifted to the higher temperature therefore indicates the proportion of 244 
the duplex that has been modified within the incubation period, though the absolute values of the 245 
melting transitions indicate the stabilization that is imparted by the bound ligand.   The result of these 246 
experiments are summarised in Table 2.  It can be seen that there is a good correlation between the 247 
large footprints produced by PBD-conjugates 9 and 10 with their greatest effect on the melting curves.  248 
At 0.5 µM 9 shifted the entire melting curve to a higher temperature with both GTATAC (Tm = 29) 249 
and GGATCC (Tm = 35) with a small amount of uncomplexed duplex (5 and 10%, respectively).  A 250 
 similar effect is seen with 10 and GTATAC for which about 30% of the transition was shifted to an 251 
even higher temperature transition.  In contrast, a significant amount of uncomplexed duplex (25%) 252 
was still evident with 10 and GGATCC, even though about 20% of the transition corresponded to a 253 
higher transition that suggested binding of a second ligand.  The melting curves with 0.5 µM 5 and 7 254 
contained a large amount of the transition that corresponded to the uncomplexed duplex.  5 and 7 had 255 
a similar effect on GGATCC, though a greater fraction of GTATAC was bound by 7. 256 
4. Discussion 257 
The anti-mycobacterial evaluation of PBD-conjugates 1-12 revealed that these compounds have 258 
remarkable growth inhibitory activity against M. tuberculosis H37Rv.  The nature and the length of the 259 
polyamide chain attached to the PBD unit had a significant influence on the molecules’ anti-microbial 260 
activity and DNA-sequence selectivity.  The presence of pyrrole rings in the polyamide chains 261 
affected the overall anti-tubercular activity of the compounds.  The di-pyrrole-containing 4 had a MIC 262 
value of 0.08 mg/L, which was comparable to those of isoniazid and rifampin, and an encouraging 263 
therapeutic window (SI = 30) that could be further improved in the second generation of PBD-based 264 
anti-tuberculosis agents.  Although displaying some degrees of cytotoxicity towards mammalian cells, 265 
PBD-conjugate 4 represents a promising anti-TB therapeutic lead, particularly in light of the results 266 
generated by the large TB drug discovery campaign recently conducted by GlaxoSmithKline (GSK).29  267 
Researchers at GSK screened a 2 million proprietary-compounds collection for anti-mycobacterial 268 
activity against M. tuberculosis H37Rv and for cytotoxicity against mammalian cells (HepG2).  A set 269 
of 177 bioactive-leads were identified displaying MIC <10 µM against H37Rv and selectivity 270 
(therapeutic) index (SI = HepG2IC50/MIC) ≥50. These values are of the same order of magnitude of 271 
those displayed by 4 (MIC = 0.13 µM and SI = 30), thus qualifying this compound as a promising 272 
lead that can be improved in subsequent medicinal chemistry work. 273 
In addition, compounds 5, 7, 9, 10 and 12, which exhibited the second best growth inhibitory activity 274 
of the series against the TB causing bacillus (MIC = 0.16 mg/L), all contained at least one pyrrole ring 275 
in their three-heterocyclic chains.  PBD-conjugates with three-imidazole (8) and three-thiazole (11) 276 
 chains showed a 2-fold and 30-fold decrease in M. tuberculosis growth inhibitory activity, 277 
respectively.  This study also showed that the antimicrobial activity of PBD-conjugates 1-12 was 278 
highly selective against slow-growing mycobacteria M. tuberculosis and M. bovis compared to fast-279 
growing bacteria E. coli, P. putida and Rhodococcus sp.  The mechanism of action of the PBDs is 280 
unique and involves the covalent binding to guanine residues within the DNA minor-groove.  The 281 
DNase I footprinting results showed that the PBD-conjugates bound with high affinity to large DNA 282 
sequences containing short A/T stretches followed by a guanine residue, with 9 protecting the 5’-283 
TAAACGTT sequence at a concentration as low as 0.5 µM.  This can be exploited to target discrete 284 
DNA sequences within the GC-rich mycobacterial genome and ultimately disrupt key enzymes and 285 
transcription factors.  DNA melting studies revealed that thiazole-containing 9, and to a lesser extent 286 
10, formed strong complexes and markedly shifted the melting curves of the two 14-mer DNA 287 
duplexes used in this study, thus confirming the significant DNA stabilisation properties of the 288 
compounds.  In summary, these results show that 1-12 could serve as DNA-targeted therapeutic leads 289 
for the treatment of tuberculosis and further studies are underway to implement the potency and 290 
therapeutic index of these compounds. 291 
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 381 
  382 
 Figure Legends 383 
 384 
Figure 1.  Schematic representation of the mechanism of action of PBDs involving the nucleophilic 385 
attack of the C2-NH2 group of a guanine residue to the N10-C11 imine moiety of PBD within the 386 
DNA minor groove.  387 
 388 
Figure 2. The library of twelve C8-linked PBD-heterocyclic polyamide conjugates 1-12 tested in this 389 
study. 390 
 391 
Figure 3.  DNase I footprinting patterns of the PBD-conjugates on the HexBrev and HexAfor DNA 392 
fragments.  The first two panels show the results in the presence of 10 µM of each of the PBD-393 
conjugates.  The second two panels show the concentration dependence of footprints on HexAfor with 394 
5 and 9.  Ligand concentrations (µM) are shown above each gel lane.  The bars indicate the location 395 
of clear footprints.  Tracks labelled GA are sequence markers specific for G and A, while con 396 
indicates DNase I cleavage in the absence of added ligand. 397 
 398 
Figure 4.  Sequences of HexAfor and HexBrev indicating the location of binding sites of the PBD-399 
conjugates (underlined and numbered in sequences).   400 
 401 
Figure 5.  Fluorescence melting profiles for the DNA duplexes 5’-F-AAAAGGATCCAAAA/5’-402 
TTTTGGATCCTTTT-Q and 5’-F-AAAAGTATACAAAA/5’-TTTTGTATACTTTT-Q (F = 403 
fluorescein and Q = dabcyl).  The ligand concentration was 0.5 µM with 0.25 µM target duplex.  404 
 405 
 406 
 407 
 408 
 409 
 410 
 411 
 412 
 413 
 414 
 415 
 Figures 416 
 417 
 418 
Figure 1 419 
 420 
 421 
 422 
 423 
Figure 2 424 
 425 
 426 
 427 
 428 
 429 
 430 
 431 
 Figure 3 432 
 433 
 434 
 435 
 436 
 437 
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 443 
HexBrev  
5’-…GGATCCATGCATTAATTCGAATATTGATCATGACGTCGACATGTACATATGTATATACG 
                                                                 1                                                        2 
 
CGCGTACGCGTATACGTAGCGCGCTTATAAGCTTGCAATTGCCGGCTAATTAGGGCCCTC 
                                   3                                          4a                                         4b 
 
GAGCTCGCGATCGGCCGGATCC-3’  
                       5 
 
HexAfor 
5’-…GGATCCCGGGATATCGATATATGGCGCCAAATTTAGCTATAGATCTAGAATTCCGGACC 
                                                                                                     6 
 
GCGGTTTAAACGTTAACCGGTACCTAGGCCTGCAGCTGCGCATGCTAGCGCTTAAGTACTAG 
                                          7                                                                                   8 
 
TGCACGTGGCCATGGATCC-3’ 
                                      9 
 
 Figure 5 444 
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 Tables 472 
 473 
Table 1.  Biological activity of PBD-conjugates 1-12. 474 
a
The SI was calculated by dividing the GIC50 for RAW264.7 by the MIC against M. tuberculosis H37Rv 475 
 476 
 477 
 478 
Table 2. Changes in melting temperature (Tm) of the oligonucleotide duplexes in the presence of 0.5 µM of each ligand and 479 
the fraction of the transition that corresponds to the uncomplexed duplex. 480 
 GGATCC 
Tm = 41.7 °C 
GTATAC 
Tm = 36.4 °C 
Tm % free Tm % free 
Py-Py-Im-PBD (5) 33 75 28 80 
Im-Im-Py-PBD (7) 30 80 28 55 
Py-Py-Th-PBD (9) 35 10 29 5 
  Py-Th-Py-PBD (10) 31 25 26 0 
 481 
 482 
483 
Compound 
MICs 
(mg/L) 
GIC50 
RAW264.7 
(mg/L) 
SIa 
Mycobacterium 
tuberculosis 
H37Rv 
Mycobacterium 
bovis BCG 
Escherichia 
coli K12 
Pseudomonas 
putida  
KT2442 
Rhodococcus 
sp. RHA1 
Py-Th-PBD (1) 0.31 0.16 1.25 >20 1.25 4.45 14.4 
Th-Py-PBD (2) 0.63 0.63 2.5 >50 5.0 2.41 3.83 
Th-Th-PBD (3) 5.19 <20 >50 >50 >50 2.41 0.46 
Py-Py-PBD (4) 0.08 0.04 1.25 10.0 1.25 2.41 30.1 
Py-Py-Im-PBD (5) 0.16 0.16 1.25 10.0 1.25 1.66 10.4 
Py-Im-Py-PBD (6) 0.32 <20 1.25 50.0 1.25 1.66 5.19 
Im-Im-Py-PBD (7) 0.16 0.08 1.25 >50 1.25 1.66 10.4 
Im-Im-Im-PBD (8) 0.32 <20 50.0 >50 10.0 1.66 5.19 
Py-Py-Th-PBD (9) 0.16 0.08 1.25 50.0 1.25 1.66 10.4 
Py-Th-Py-PBD (10) 0.16 0.08 1.25 >50 1.25 1.66 10.4 
Th-Th-Th-PBD (11) 5.19 ND >50 >50 >50 1.66 0.32 
Py-Py-Py-PBD (12) 0.16 0.04 1.25 5.0 1.25 1.66 10.4 
Isoniazid 0.05 0.05 ND ND ND 3000 60000 
Rifampin 0.05 0.05 ND ND ND 700 14000 
Kanamycin ND ND 1.0 1.0 10.0 ND ND 
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